ATGen manufactures and distributes a large selection of recombinant proteins and monoclonal antibodies to over 200 research institutes in over 20 different countries.
The company has also developed and launched an innovative NK Cell function test called NK VUE to help doctors diagnose diseases that are known to affect NK Cell activity. NK VUE bears CE Marking and has been approved by the KFDA and Health Canada.
As of 2016, ATGen has over 100 employees and keeps growing. The company's vision to save as many lives as possible is further reinforced by ATGen’s current development of immunotherapies.